文献速递心脑血管急症

可溶性低密度脂蛋白受体相关蛋白-1水平在心肌心包炎与急性冠脉综合征鉴别诊断中的价值

Soluble low density lipoprotein receptor-related protein-1 levels in the differential diagnosis of myopericarditis versus acute coronary syndrome.
PubMed 文献 · Am J Emerg Med · 2022-07-18
一句话结论急诊胸痛且肌钙蛋白升高的患者中,sLRP-1以4.3 μg/ml为界值诊断心肌心包炎的敏感性69%、特异性85%,可能有助于与ACS鉴别。

本研究纳入2018年1月1日至2019年1月1日因胸痛且肌钙蛋白升高到急诊就诊、诊断为心肌心包炎或急性冠脉综合征的连续患者,并设健康对照组(n=61),入院时检测血清sLRP-1。心肌心包炎组sLRP-1中位数(IQR)为7.39(22.42)μg/ml,显著高于对照组2.27(1.74)μg/ml(p=0.005)和ACS组2.41(0.98)μg/ml(p=0.001),三组总体p=0.004。多因素分析中仅sLRP-1可区分心肌心包炎与ACS(OR=1684,p=0.046,95%CI 1008-2812);ROC曲线下面积0.79(95%CI 0.62-0.95,p=0.001),以4.3 μg/ml为界值诊断心肌心包炎的敏感性69%、特异性85%。作者认为sLRP-1是急诊鉴别心肌心包炎与ACS的潜在生物标志物,未来需进一步研究评估其诊断和预后价值。

要点

  • 急诊胸痛且肌钙蛋白升高的患者中,心肌心包炎组sLRP-1中位数7.39(22.42)μg/ml,高于ACS组2.41(0.98)μg/ml(p=0.001)和健康对照组2.27(1.74)μg/ml(p=0.005)。
  • 在sLRP-1、年龄、性别、HDL-C和LDL-C这些协变量中,仅sLRP-1可区分心肌心包炎与ACS(OR=1684,p=0.046,95%CI 1008-2812)。
  • 以4.3 μg/ml为界值,sLRP-1诊断心肌心包炎的敏感性69%、特异性85%,ROC曲线下面积0.79(95%CI 0.62-0.95,p=0.001)。
  • 作者认为sLRP-1是急诊鉴别心肌心包炎与ACS的潜在生物标志物,未来需进一步研究评估其诊断和预后价值。

适用人群与场景

  • 2018年1月1日至2019年1月1日因胸痛且肌钙蛋白升高到急诊就诊、诊断为心肌心包炎或急性冠脉综合征的连续患者;对照组为健康受试者(n=61)。

诊断标准与关键阈值

  • sLRP-1诊断心肌心包炎的界值为4.3 μg/ml,对应敏感性69%、特异性85%。

研究设计与关键结果

  • 研究纳入因胸痛且肌钙蛋白升高到急诊就诊、诊断为心肌心包炎或急性冠脉综合征的连续患者,并设健康对照组(n=61),入院时检测血清sLRP-1。
  • 心肌心包炎组sLRP-1中位数(IQR)为7.39(22.42)μg/ml,对照组为2.27(1.74)μg/ml,ACS组为2.41(0.98)μg/ml,三组比较p=0.004;心肌心包炎组高于对照组(p=0.005)和ACS组(p=0.001)。
  • 在sLRP-1、年龄、性别、HDL-C和LDL-C这些协变量中,仅sLRP-1可区分心肌心包炎与ACS(OR=1684,p=0.046,95%CI 1008-2812)。
  • ROC分析曲线下面积为0.79(95%CI 0.62-0.95,p=0.001);以4.3 μg/ml为界值诊断心肌心包炎的敏感性69%、特异性85%。

证据类型、等级与局限

  • 证据类型:研究论文(病例对照研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为sLRP-1是急诊鉴别心肌心包炎与ACS的潜在生物标志物,未来需进一步研究评估其诊断和预后价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Differential diagnosis of myopericarditis (MPC) versus acute coronary syndromes (ACS) can be difficult in the emergency room (ER). Low density lipoprotein receptor-related protein-1 (LRP-1) is a transmembrane receptor with diverse biological functions. LRP-1 is increased after viral infections as a defense mechanism. sLRP-1 (soluble form) can be measured in the serum. We study the diagnostic sLRP-1 levels in patients with MPC, ACS and healthy controls.

METHODS: The study included consecutive patients who were admitted between the dates of 1.1.2018 and 1.1.2019 with the diagnosis of MPC or ACS. All patients reported to the ER with chest pain (CP) and elevated cardiac troponin levels. Control group (n = 61) was selected from healthy subjects. In addition to routine laboratory work up, serum sLRP-1 concentrations were measured on admission.

RESULTS: sLRP-1 levels were significantly higher in MPC, compared to controls (p = 0.005) and ACS (p = 0.001). Median (IQR) sLRP-1 levels in MPC, controls and ACS were 7.39 (22.42), 2.27 (1.74), 2.41 (0.98) μg/ml, respectively (p = 0.004). Among the covariates: sLRP-1, age, gender, HDL-C and LDL-C; only sLRP-1 differentiated a diagnosis of MPC versus ACS (OR = 1684, p = 0,046, CI for OR (1008-2812). The area under the curve (AUC) was measured as 0.79 [CI 0.62-0.95] in ROC analysis, p = 0.001; sLRP-1 had 69% sensitivity and 85% specificity for diagnosis of MPC with a cut-off value of 4.3 μg/ml.

CONCLUSION: sLRP-1 is a potential biomarker in the differential diagnosis of MPC versus ACS in ER. Future studies are needed to evaluate and develop the utility of sLRP-1 as a diagnostic and prognostic biomarker in MPC.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Agirbasli M, Bölen F, Konal O, et al. Soluble low density lipoprotein receptor-related protein-1 levels in the differential diagnosis of myopericarditis versus acute coronary syndrome. Am J Emerg Med. 2022. PMID: 35878570. doi:10.1016/j.ajem.2022.07.038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。